The human papillomavirus vaccine: A powerful tool for the primary prevention of cervical cancer;La vacuna contra el virus del papiloma humano: Una gran arma para la prevención primaria del cáncer de cuello uterino

Colombia Medica

Volumn 39, Issue 2, 2008, Pages 196-204

  Muñoz, Nubia ^a,d   Reina, Julio César ^b   Sánchez, Gloria Inés ^c  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSIDAD DEL VALLE   (Colombia)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^d Instituto Nacional de Cancerología   (Colombia)

Author keywords

Cervix neoplasms prevention; Condylomata acuminata; Oncogenic viruses; Papillomavirus vaccines; Prevention control; Uterine cervical neoplasms; Vaginal neoplasms; Vulvar neoplasms; Warts

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COLOMBIA; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; HEALTH CARE ACCESS; HUMAN; NONHUMAN; PRECANCER; PRIMARY PREVENTION; REVIEW; SENSITIVITY AND SPECIFICITY; SOUTH AND CENTRAL AMERICA; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VULVA TUMOR;

EID: 52949101285     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5, version 2.0. Lyon: IARCPress; 2004.
2. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004; 109: 418-24.
3. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine. 2006; 24 Suppl 3: 63-70.
4. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; 24 Suppl 3: 11-25.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-9.
6. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-27.
7. Castellsagué X, Bosch X, Muñoz N, Meijer C, Shah K, de Sanjosé S, et al. Male circumcision, penile human papillomavirus infection and cervical cancer. N Engl J Med. 2002; 346: 1105-12.
8. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006; 354: 2645-54.
9. Plotkin SA. Vaccines, vaccination, and vaccinology. J Infect Dis. 2003; 187: 1349-59.
10. Kahn JA. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health. 2005; 37 Suppl 6: 10-6.
11. Organización Panamericana de la Salud. Protegiendo la salud de las Américas: Avanzando de la vacunación de los niños a la de la familia. XVII Reunión del Grupo Técnico Asesor sobre Enfermedades Prevenibles por Vacunación. Ciudad de Guatemala, Guatemala 25-27 de julio de 2006. Washington DC: OPS; 2006.
12. Organización Panamericana de la Salud. Control de la Difteria, tos ferina, tétanos, Haemophilus influenzae tipo b y hepatitis B: Guía práctica. Publicación Científica y Técnica No 604. Washington, D.C.: OPS; 2006.
13. Zhou J, Sun XY, Davies H, Crawford L, Park D, Frazer IH. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology. 1992; 189: 592-9.
14. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006; 116: 1167-73.
15. Pagliusi SR, Aguado TM. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004; 23: 569-78.
16. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369: 1861-8.
17. Joura EA, Leodolter S, Hernández-áAvila M, Wheeler CM, Pérez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007; 369: 1693-702.
18. Pérez G, Lazcano-Ponce E, Hernández-Ávila M, García PJ, Muñoz N, Villa LL, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008; 122: 1311-8.
19. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118: 2135-45.
20. Luna J, Saah A, Hood S, Barr E, & The FUTURE III Steering Committee. The Safety, efficacy and immunogenicity of quadrivalent HPV (types 6/ 11/16/18) L1 virus-like-particle (VLP) vaccine in women aged 24 to 45. 24th International Papillomavirus Conference & Clinical Workshop. Beijing, 3-9 November, 2007.
21. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in youngwomen: a randomised controlled trial. Lancet. 2004; 364: 1757-65.
22. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-upfrom a randomised control trial. Lancet 2006; 367: 1247-55.
23. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustainedefficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95: 1459-66.
24. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007; 25: 4931-9.
25. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recomendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 1-24.
26. Profamilia Colombia. Encuesta Nacional de Demografía y Salud (ENDS 2005). [en línea] 2005. [Fecha de acceso: 16 de agosto de 2007]. Disponible en: htt://www.profamilia.org.co/encuestas/01encuestas/ 2005resultado_generales.htm
27. Reina JC, Bravo LE, de Orozco B. El reción nacido hijo de madre adolescente. En: XXV Congreso Colombiano de Pediatría, Medellín, Colombia. Junio 14-16 de 2007.
28. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillornavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366: 991-8.
29. The Future II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007; 196: 1438-46.
30. Harper DM, Paavonen J. Age for HPV vaccination. Vaccine. 2008; 26 Suppl 1: A7-A11.
31. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 virus-likeparticle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298: 743-53.
32. Hildesheim A, Herrero R. Human papillomavirus vaccine should be given before sexual debut for maximum benefit [editorial commentary]. J Infect Dis. 2007; 196: 1431-2.
33. Brabin L, Roberts SA, Kitchener HC. A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. BMC Public Health. 2007; 7: 20.
34. Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine. 2006; 24: 3087-94.
35. Hanisch R, Gustat J, Hagensee ME, Baena A, Salazar JE, Castro MV, et al. Knowledge of Pap screening and human papillomavirus among women attending clinics in Medellín, Colombia. Int J Gynecol Cancer. En prensa 2008.
36. Goldie SJ. A public health approach to cervical cancer control: considerations of screening and vaccination strategies. Int J Gynaecol Obstet. 2006; 94 Suppl 1: 95-105.
37. Goldie SJ, Goldbaber-Fiebert JD, Garnett GP. Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. Vaccine. 2006; 24 Suppl 3: 155-63.
38. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea M& et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007; 25: 6257-70.
39. Clifford G, Franceschi S, Díaz M, Muñoz N, Villa LI. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24 Suppl 3: 26-34.
40. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and managementof non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006; 24 Suppl. 3: 35-41.
41. Franco EL, Cuzick J, Hildesheim. A, de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006; 24 Suppl 3: 171-7.
42. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of BPV testing: A summary of meta-analyses. Vaccine. 2006; 24 Suppl 3: 78-89.
43. Almonte M, Ferreccio C, Winkler JL, Cuzick J, Tsu V, Robles S, et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Perú. .Int J Cancer. 2007; 121: 796-802.
44. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007;370:398-406.
45. Muñoz N. New perspective for cervical cancer prevention based on human papillomavirus. Biomedica. 2006;26: 471-4.